Td Asset Management Inc Adc Therapeutics Sa Transaction History

Td Asset Management Inc

  • $107 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 07, 2022
SELL
$4.66 - $10.31 $82,016 - $181,456
-17,600 Reduced 19.07%
74,690 $365,000
Q3 2021

Nov 09, 2021
BUY
$20.45 - $30.0 $163,600 - $240,000
8,000 Added 9.49%
92,290 $2.51 Million
Q1 2021

May 14, 2021
BUY
$22.75 - $34.05 $723,472 - $1.08 Million
31,801 Added 60.59%
84,290 $2.06 Million
Q4 2020

Feb 16, 2021
BUY
$25.26 - $38.02 $1.33 Million - $2 Million
52,489 New
52,489 $1.68 Million

Others Institutions Holding ADCT

# of Institutions
80
Shares Held
55.1M
Call Options Held
82.7K
Put Options Held
31.5K
View Full List

About ADC Therapeutics SA

ADCT Quotes by TradingView
  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $175M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Td Asset Management Inc Portfolio

Follow Td Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email